These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 9481614

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists.
    Davies GJ, Tzivoni D, Kobrin I.
    Am J Cardiol; 1997 Aug 21; 80(4B):34C-39C. PubMed ID: 9286852
    [Abstract] [Full Text] [Related]

  • 3. Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
    Kobrin I, Bieska G, Charlon V, Lindberg E, Pordy R.
    Cardiology; 1998 Aug 21; 89 Suppl 1():23-32. PubMed ID: 9570426
    [Abstract] [Full Text] [Related]

  • 4. Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists.
    Massie BM, Lacourcière Y, Viskoper R, Woittiez A, Kobrin I.
    Am J Cardiol; 1997 Aug 21; 80(4B):27C-33C. PubMed ID: 9286851
    [Abstract] [Full Text] [Related]

  • 5. Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris.
    Massie BM.
    Am J Hypertens; 1998 Apr 21; 11(4 Pt 3):95S-102S. PubMed ID: 9607373
    [Abstract] [Full Text] [Related]

  • 6. Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.
    Kobrin I, Charlon V, Lindberg E, Pordy R.
    Am J Cardiol; 1997 Aug 21; 80(4B):40C-46C. PubMed ID: 9286853
    [Abstract] [Full Text] [Related]

  • 7. Antianginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris.
    Alpert JS, Bakx AL, Braun S, Frishman WH, Schneeweiss A, Tzivoni D, Kobrin I.
    Am J Cardiol; 1997 Aug 21; 80(4B):20C-26C. PubMed ID: 9286850
    [Abstract] [Full Text] [Related]

  • 8. Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris.
    Brogden RN, Markham A.
    Drugs; 1997 Nov 21; 54(5):774-93. PubMed ID: 9360062
    [Abstract] [Full Text] [Related]

  • 9. Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group on Cardiovascular Research (WCN).
    Van Der Vring JA, Daniëls MC, Holwerda NJ, Withagen PJ, Schelling A, Cleophas TJ, Hendriks MG.
    Br J Clin Pharmacol; 1999 May 21; 47(5):493-8. PubMed ID: 10336572
    [Abstract] [Full Text] [Related]

  • 10. Combination of calcium channel blockers and beta blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. The Netherlands Working Group on Cardiovascular Research (WCN).
    van der Vring JA, Daniëls MC, Holwerda NJ, Withagen PJ, Schelling A, Cleophas TJ, Hendriks MG.
    Angiology; 1999 Jun 21; 50(6):447-54. PubMed ID: 10378820
    [Abstract] [Full Text] [Related]

  • 11. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.
    Braun S, van der Wall EE, Emanuelsson H, Kobrin I.
    J Am Coll Cardiol; 1996 Feb 21; 27(2):317-22. PubMed ID: 8557900
    [Abstract] [Full Text] [Related]

  • 12. Long-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with sustained-release diltiazem.
    Davies GJ, Kobrin I, Caspi A, Reisin LH, de Albuquerque DC, Armagnijan D, Coelho OR, Schneeweiss A.
    Am Heart J; 1997 Aug 21; 134(2 Pt 1):220-8. PubMed ID: 9313601
    [Abstract] [Full Text] [Related]

  • 13. Additional antianginal and anti-ischemic efficacy of mibefradil in patients concomitantly treated with long-acting nitrates for chronic stable angina pectoris.
    Frishman WH, Bittar N, Glasser S, Habib G, Smith W, Pordy R.
    Clin Cardiol; 1998 Jul 21; 21(7):483-90. PubMed ID: 9669057
    [Abstract] [Full Text] [Related]

  • 14. Combination of calcium channel blockers and beta-blockers for patients with exercise-induced angina pectoris: beneficial effect of calcium channel blockers largely determined by their effect on heart rate.
    Cleophas TJ, van der Sluijs J, van der Vring JA, Daniëls MC, Holwerda KJ, Withagen AJ, Schelling A, Hendriks MG, Zwinderman AH.
    J Clin Pharmacol; 1999 Jul 21; 39(7):738-46. PubMed ID: 10392329
    [Abstract] [Full Text] [Related]

  • 15. Adding the new calcium antagonist mibefradil to patients receiving long-term beta-blocker therapy results in improved antianginal and antiischemic efficacy.
    Schneeweiss A, Kobrin I, Charlon V, Caspi A, Marmor A, Sclarovsky S, Reisin L, Schlesinger Z.
    Am Heart J; 1998 Feb 21; 135(2 Pt 1):272-80. PubMed ID: 9489976
    [Abstract] [Full Text] [Related]

  • 16. Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris.
    Alpert JS, Kobrin I, DeQuattro V, Friedman R, Shepherd A, Fenster PE, Thadani U.
    Am J Cardiol; 1997 Apr 15; 79(8):1025-30. PubMed ID: 9114758
    [Abstract] [Full Text] [Related]

  • 17. Mibefradil, a T-channel-selective calcium antagonist: clinical trials in hypertension.
    Oparil S.
    Am J Hypertens; 1998 Apr 15; 11(4 Pt 3):88S-94S. PubMed ID: 9607372
    [Abstract] [Full Text] [Related]

  • 18. Mibefradil: a selective T-type calcium antagonist.
    Massie BM.
    Am J Cardiol; 1997 Nov 06; 80(9A):23I-32I. PubMed ID: 9375939
    [Abstract] [Full Text] [Related]

  • 19. Mibefradil: a new class of calcium-channel antagonists.
    Billups SJ, Carter BL.
    Ann Pharmacother; 1998 Jun 06; 32(6):659-71. PubMed ID: 9640486
    [Abstract] [Full Text] [Related]

  • 20. Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension.
    Oparil S, Bernink P, Bursztyn M, Carney S, Kobrin I.
    Am J Cardiol; 1997 Aug 21; 80(4B):12C-19C. PubMed ID: 9286849
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.